Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
作者信息
Cubero Daniel I G, Del Giglio Auro
机构信息
Department of Oncology and Haematology, ABC Foundation School of Medicine, Av. Principe de Gales, n.821, anexo 3, Santo André/SP, 09060-650, Brazil.
出版信息
Ther Adv Med Oncol. 2013 Jan;5(1):93-4. doi: 10.1177/1758834012469430.
Abstract
摘要
相似文献
1
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
Ther Adv Med Oncol. 2013 Jan;5(1):93-4. doi: 10.1177/1758834012469430.
2
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
Ther Adv Med Oncol. 2012 Jul;4(4):167-72. doi: 10.1177/1758834012441049.
3
Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
J Surg Oncol. 2002 Oct;81(2):87-92. doi: 10.1002/jso.10137.
4
Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
Chemotherapy. 2007;53(6):442-5. doi: 10.1159/000110016. Epub 2007 Oct 22.
5
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cancer Res. 1995 Dec 15;55(24):6227-30.
6
UFT in the treatment of colorectal and breast cancer.
Oncology (Williston Park). 2001 Jan;15(1 Suppl 2):49-56.
7
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.
Ther Adv Med Oncol. 2013 Jan;5(1):91-2. doi: 10.1177/1758834012464806.
8
Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.
BMC Cancer. 2011 Mar 16;11:98. doi: 10.1186/1471-2407-11-98.
9
Uracil-tegafur in gastric carcinoma: a comprehensive review.
J Clin Oncol. 1998 Aug;16(8):2877-85. doi: 10.1200/JCO.1998.16.8.2877.
10
Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Oncol Rep. 2007 Jan;17(1):153-9.
引用本文的文献
1
The Prognostic and Predictive Value of Dihydropyrimidine Dehydrogenase-Related Indicators in Clinical Outcomes of Chemotherapy in Colorectal Cancer Patients: a Systematic Review and Meta-Analysis.
Pathol Oncol Res. 2020 Jan;26(1):121-131. doi: 10.1007/s12253-018-00563-3. Epub 2018 Dec 5.
2
Germline oncopharmacogenetics, a promising field in cancer therapy.
Cell Oncol (Dordr). 2015 Feb;38(1):65-89. doi: 10.1007/s13402-014-0214-4. Epub 2015 Jan 9.
本文引用的文献
1
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.
Ther Adv Med Oncol. 2013 Jan;5(1):91-2. doi: 10.1177/1758834012464806.
2
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
Ther Adv Med Oncol. 2012 Jul;4(4):167-72. doi: 10.1177/1758834012441049.
3
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
Ann Intern Med. 2010 Dec 7;153(11):767-8. doi: 10.7326/0003-4819-153-11-201012070-00023.
4
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
Clin Cancer Res. 2006 Sep 15;12(18):5491-5. doi: 10.1158/1078-0432.CCR-06-0747.
5
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
J Clin Oncol. 2002 Sep 1;20(17):3617-27. doi: 10.1200/JCO.2002.10.129.
6
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
J Clin Oncol. 2002 Sep 1;20(17):3605-16. doi: 10.1200/JCO.2002.04.123.
7
8
9
Population study of dihydropyrimidine dehydrogenase in cancer patients.
J Clin Oncol. 1994 Nov;12(11):2248-53. doi: 10.1200/JCO.1994.12.11.2248.
Zotero 插件